Zhoufeng Wang,Kailing Tu,Lin Xia,Kai Luo,Wenxin Luo,Jie Tang,Keying Lu,Xinlei Hu,Yijing He,Wenliang Qiao,Yongzhao Zhou,Jun Zhang,Feng Cao,Shuiping Dai,Panwen Tian,Ye Wang,Lunxu Liu,Guowei Che,Qinghua Zhou,Dan Xie,Weimin Li

Abstract:<p>SF1:Table S1. The Clinical information and pathologic characteristics of 47 NSCLC patients and 4 non-malignant nodules patients; SF2:Table S2. Information of DNA-seq, RNA-seq, ATAC-seq and single-cell ATAC-seq; SF3:Table S3. Significant amplication and deletion regions of LUAD and LUSC samples (Genes marked in red were known cancer genes); SF4:Table S4. GREAT enrichment of common open regions; SF5:Table S5. Expression change of cluster II specific open peak related genes. SF6:Table S6. Sample Information and classification; SF7:Table S7. Sub cluster 2 specific region GREAT enrichment; SF8:Table S8. broad open chromatin region related genes; SF9:Table S9. sCOP and their accosiated DEGs; SF10:Table S10. Known important NSCLC related genes were affected by sCOP; SF11:Table S11. Joint-QTLs and Genes; SF12:Table S12. Haplotype blocks harboring both joint-QTL and GWAS lead SNP of lung cancer;</p>

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures 1 - 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 3 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Results from CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma

Supplementary Table 1 from Multistage Analysis of Variants in the Inflammation Pathway and Lung Cancer Risk in Smokers

Supplementary Table S4 from Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival

Additional File 3 of Bioinformatics Integrated Analysis to Investigate Candidate Biomarkers and Associated Metabolites in Osteosarcoma

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Tables from The Open Chromatin Landscape of Non–Small Cell Lung Carcinoma

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table 3 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Additional File 3: Table S2. of A Novel Integrated Gene Coexpression Analysis Approach Reveals a Prognostic Three-Transcription-factor Signature for Glioma Molecular Subtypes

Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma